Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Health Enhancement Products, Inc. University of Yaounde |
---|---|
Information provided by: | Health Enhancement Products, Inc. |
ClinicalTrials.gov Identifier: | NCT00489333 |
The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a novel fermentation product of a freshwater algae ecosystem) vs. placebo on Metabolic Syndrome and indicators of cardiovascular health including: body weight and fat, blood lipids, inflammatory markers such as hsCRP, blood pressure and fasting blood glucose.
Condition | Intervention |
---|---|
Metabolic Syndrome X |
Drug: ProAlgaZyme |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | The Effects of ProAlgaZyme Novel Algae Infusion vs. Placebo on Metabolic Syndrome and Markers of Cardiovascular Health |
Enrollment: | 52 |
Study Start Date: | May 2006 |
Study Completion Date: | September 2006 |
Metabolic syndrome, a set of symptoms strongly associated with increased risk for both cardiovascular disease and diabetes, is generally linked to obesity and has become a serious problem in many industrialized countries. Agents that aid in weight loss or help to normalize blood lipids or inflammation may reduce the risk of metabolic syndrome and therefore, reduce the risk of cardiovascular disease and diabetes. This study is a single-center, double-blind, placebo-controlled, parallel design, to evaluate the effects of ProAlgaZyme (4 fl. oz. daily) on metabolic syndrome and markers of cardiovascular health including blood lipids, inflammatory markers and anthropometric measurements.
Comparisons: ProAlgaZyme vs. placebo [Time frame: 10 weeks]
Ages Eligible for Study: | 25 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Participants must meet 3 of the following criteria:
Exclusion Criteria:
Cameroon | |
Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I | |
Yaounde, Cameroon |
Principal Investigator: | Julius Oben, Ph.D. | Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon |
Study ID Numbers: | H-0001-01, 087/2006 |
Study First Received: | June 19, 2007 |
Last Updated: | June 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00489333 |
Health Authority: | Cameroon: Ministry of Public Health |
ProAlgaZyme Metabolic syndrome Inflammation Cardiovascular |
hsCRP Lipids Algae |
Hyperinsulinism Metabolic Diseases Metabolic Syndrome X Syndrome X Insulin Resistance |
Metabolic disorder Glucose Metabolism Disorders Abdominal obesity metabolic syndrome Inflammation |
Pathologic Processes Disease Syndrome |